Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177002 | 0.86 | CPN1 (0.38) | BACE1AOC3L3MBTL1ALOX5MEN1 | |
| SCHEMBL2240112 | 0.79 | SSTR4 (0.37) | BACE1CPN1CPB2ADRB3AURKA | |
| SCHEMBL2240105 | 0.79 | SSTR4 (0.37) | BACE1CPN1CPB2ADRB3AURKA | |
| SCHEMBL16824910 | 0.77 | AOC3 (0.43) | BACE1AOC3L3MBTL1MEN1KMT2A | |
| SCHEMBL7120679 | 0.73 | ADRB3 (0.43) | BACE1ADRB3ADRB2ADRB1 | |
| SCHEMBL7120686 | 0.73 | ADRB3 (0.43) | BACE1ADRB3ADRB2ADRB1 | |
| SCHEMBL7694265 | 0.71 | ADRB3 (0.46) | BACE1AOC3MEN1KMT2AADRB3 | |
| SCHEMBL7122416 | 0.71 | ADRB3 (0.46) | BACE1AOC3MEN1KMT2AADRB3 | |
| SCHEMBL7122412 | 0.71 | ADRB3 (0.46) | BACE1AOC3MEN1KMT2AADRB3 | |
| SCHEMBL1625898 | 0.70 | BACE1 (0.47) | BACE1AOC3MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | BACE1 1152/4885AOC3 973/4885L3MBTL1 3039/4885 |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | BACE1 257/4885AOC3 498/4885L3MBTL1 2944/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | BACE1 413/4885AOC3 722/4885L3MBTL1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.